206-838-5110 ext. 102 general@etubics.com

Selected Publications

Below is a selection of publications that are associated with Etubics next generation adenovirus vector.

Cancer Immunology, Immunotherapy May 2015
Extended evaluation of a Phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late stage colorectal cancer.

Cancer Immunology, Immunotherapy June 2013
Novel Adenoviral Vector Induces T-Cell Responses Despite Anti-Adenoviral Neutralizing Antibodies in Colorectal Cancer Patients.

Vaccine, November 2012
Control of SIV Infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5[E1,E2b-] vector platform.

Cancer Gene Therapy, August 2012
A Non-Oncogenic HPV16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors

Clinical & Cellular Immunology, December 2012
New Recombinant Ad5 Vector Overcomes Ad5 Immunity Allowing for Multiple Safe, Homologous Immunizations

Vaccine, October 2011
Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine

Vaccine, September 2011
Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

Cancer, Gene Therapy May 2011
An Ad5[E2-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice

Cancer Immunol Immunotherapy, July 2010
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

Expert Opinion on Biological Therapy, December 2009
Overcoming pre-existing Adenovirus immunity by genetic engineering of adenovirus-based vaccine vectors

Vaccine, October 2009
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

Cancer Gene Therapy, February 2009
Optimization of vaccine responses with an E1, E2b and E3- deleted Ad5 vector circumvents pre-existing anti-vector immunity.

Immunology Letters, November 2008
A Preliminary and Comparative Evaluation of a Novel Ad5 [E1-, Eb2-] Recombinant Based Vaccine Used to Induce Cell Mediated Immune Responses

Gene Therapy, October 1999
Next generation adenoviral vectors: new and improved.

Journal of Virology, February 1998
Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted

Gene Therapy, March 1997
Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy

Proceedings of the National Academy of Sciences of the United States of America, April 1996
Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors.

Contact Us

(206) 838-5110 ext. 102